Loading...
Loading...
Forest Laboratories, Inc.
FRX announced today that its Canadian
subsidiary, Forest Laboratories Canada Inc. has received a Notice of
Compliance from Health Canada for BYSTOLIC® (nebivolol) tablets, a once daily
beta blocker for the treatment of hypertension.
“We are pleased that Health Canada has granted approval for BYSTOLIC. This is
an important milestone for Forest, as it is the first product approved for our
newly established Canadian subsidiary. We look forward to bringing additional
innovative Forest products to the Canadian market,” commented David Solomon,
Senior Vice President of Corporate Development and Strategic Planning, Forest
Laboratories, Inc.
BYSTOLIC is expected to be available to Canadian patients in Q2 2013.
Forest Laboratories Canada Inc. operations are based in Toronto, Ontario. To
learn more, visit www.frx.ca.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in